Winkler G Weinberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Winkler G Weinberg has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- C Tracey Lancaster
Infectious Diseases, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
1 shared publication C Tracey Pakes
1 shared publication- Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
1 shared publication - Gary E Pakes
Infectious Diseases, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
1 shared publication - Keith Pappa
10GlaxoSmithKline, Research Triangle Park, Durham, NC, USA
1 shared publication - Kimberly Y. Smith
Department of Medicine Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois
1 shared publication
Latest Publications
- Open Access
- 1 January 2008
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 5 (1) , 5
Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-label, multicenter 48-week study (ALERT) in 106 antiretroviral-naïve, HIV-infected patients (median HIV-1 RNA 4.9 log10 copies/mL; CD4+ count 191 cells/mm3) randomly assigned to the FPV/r100 or ATV/r100 regimens.
- 1 January 2008
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 5 (1) , 5
Open AccessFosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
Once-daily (QD) ritonavir 100 mg-boosted fosamprenavir 1400 mg (FPV/r100) or atazanavir 300 mg (ATV/r100), plus tenofovir/emtricitabine (TDF/FTC) 300 mg/200 mg, have not been compared as initial antiretroviral treatment. To address this data gap, we conducted an open-label, multicenter 48-week study (ALERT) in 106 antiretroviral-naïve, HIV-infected patients (median HIV-1 RNA 4.9 log10 copies/mL; CD4+ count 191 cells/mm3) randomly assigned to the FPV/r100 or ATV/r100 regimens.